Cantor Fitzgerald Issues Pessimistic Forecast for Harrow (NASDAQ:HROW) Stock Price

Harrow (NASDAQ:HROW) had its price objective cut by research analysts at Cantor Fitzgerald from $94.00 to $91.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 135.75% from the stock’s previous close.

A number of other brokerages have also recently weighed in on HROW. HC Wainwright upped their price target on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday. Zacks Research lowered shares of Harrow from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. LADENBURG THALM/SH SH increased their target price on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of Harrow in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.14.

Harrow Price Performance

Shares of Harrow stock opened at $38.60 on Wednesday. Harrow has a twelve month low of $20.85 and a twelve month high of $54.85. The company has a debt-to-equity ratio of 5.21, a quick ratio of 2.52 and a current ratio of 2.72. The firm has a market cap of $1.43 billion, a P/E ratio of -227.05 and a beta of 0.05. The firm’s 50-day simple moving average is $48.41 and its 200-day simple moving average is $43.79.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.23). Harrow had a negative net margin of 1.89% and a positive return on equity of 36.76%. The company had revenue of $89.09 million for the quarter, compared to analyst estimates of $88.42 million. As a group, research analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Harrow

A number of large investors have recently modified their holdings of HROW. Vanguard Group Inc. increased its holdings in shares of Harrow by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 1,921,683 shares of the company’s stock valued at $94,162,000 after purchasing an additional 50,889 shares in the last quarter. Geode Capital Management LLC boosted its position in Harrow by 4.7% in the 2nd quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock valued at $24,765,000 after buying an additional 36,724 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Harrow by 31.5% in the 2nd quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock valued at $17,251,000 after buying an additional 135,202 shares during the period. Penn Capital Management Company LLC increased its stake in shares of Harrow by 20.5% in the 4th quarter. Penn Capital Management Company LLC now owns 392,067 shares of the company’s stock valued at $19,257,000 after buying an additional 66,589 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Harrow by 32.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 370,548 shares of the company’s stock worth $18,159,000 after acquiring an additional 90,331 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow News Summary

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Record revenue, margin progress and cash generation: Harrow reported Q4 revenue of $89.1M (33% YoY) and full‑year 2025 revenue of $272.3M (36% YoY); adjusted EBITDA rose to $61.9M for 2025 and operating cash flow turned positive ($43.9M). These fundamentals support longer‑term growth prospects. Q4 Results
• Positive Sentiment: Clinical progress: the FDA cleared an IND to support a planned Phase 3 trial for TRIESENCE to expand its label for post‑cataract inflammation and pain — a successful program could add a higher‑value indication. Phase 3 IND
• Positive Sentiment: Investor outreach: management will present at Leerink Partner’s Global Healthcare Conference (Mar 10), offering an opportunity to clarify strategy and guidance execution. Conference Presentation
• Neutral Sentiment: Full Q4 earnings call and slide deck are available for deeper inspection of unit trends (product mix, ImprimisRx shift toward higher‑margin items) and management commentary. Investors should review the transcript/slides for details. Earnings Call Transcript
• Negative Sentiment: EPS miss and mixed metrics: Harrow’s reported EPS missed consensus (company reported an EPS shortfall vs. expectations) even as revenue broadly met estimates — the profit miss is weighing on sentiment. Earnings Miss
• Negative Sentiment: FY2026 revenue guidance of $350M–$365M and Adjusted EBITDA $80M–$100M came in well below the consensus (~$394M), signaling growth that management expects to be back‑loaded; markets view the guidance shortfall as the primary near‑term negative driver. Guidance
• Negative Sentiment: Analyst downgrade and leverage concerns: a Seeking Alpha note downgraded HROW to “Sell,” highlighting persistent low margins, high leverage and rising interest expense that could constrain cash flow if growth is costly — contributing to downside pressure. Analyst Downgrade

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.